Digging into Alnylam's recent topline vutrisiran data from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM)

Executed on:Jul 15, 2024 2:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Stanford Cardiologist and Instructor at Stanford University School of Medicine.
Manages patients at the amyloid center at Stanford and directs the amyloid clinic at the Palo Alto VA.
Research focuses on Investigating the molecular mechanisms behind genetic risk factors for human cardiovascular disease focusing on amyloidosis, cardio-oncology, and atherosclerotic diseases.

Interview Goal

This interview aims to delve into the recent developments and clinical data adjustments in Alnylam Pharmaceuticals' HELIOS-B trial. The focus is to understand the new data for the efficacy and future potential of vutrisiran in treating transthyretin amyloidosis (ATTR) in cardiomyopathy.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.